|Security||ENV / Envestnet, Inc. (29404K106)|
|Industry||Business Services, Not Elsewhere Classified|
|Common Shares Outstanding||45,215,812 shares (as of 2018-03-31)|
Stock Insider Trading (from SEC Form 4)
Envestnet, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
ENV / Envestnet, Inc. insiders include Roame Charles, Aguilar Luis A, and CHAPIN ROSS K, O'Brien Shelly, CROWELL GAYLE A, Smith Gregory A, Crager William, Thomas Brandon, Egan Cynthia, D'Arrigo Peter, Bergman Judson, FOX JAMES L, Arora Anil, Sisteron Yves, Johnson James, Mayer Joshua, Cooper Barry D. Grinis Scott D, Majoros Matthew, .
CROWELL GAYLE A
Grinis Scott D
Cooper Barry D.
Smith Gregory A
FOX JAMES L
CHAPIN ROSS K
Aguilar Luis A
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||CROWELL GAYLE A By trust||S||X||I||59.05||-133||4,118||243,168|
|4||Grinis Scott D||F||D||56.20||-193||203,271|
|4||CROWELL GAYLE A By trust||S||X||I||54.35||-2,934||4,251||231,042|
|4||Grinis Scott D||F||D||54.55||-94||203,464|
|4||Grinis Scott D||F||D||56.85||-1,009||203,558|
|4||CROWELL GAYLE A By trust||S||X||I||57.10||-745||7,185||410,264|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
SS&C Technologies Holdings, Inc (NASDAQ: SSNC) trades at a P/E multiple of 39.4x, which is higher than the Information Technology sector median of 30.0x. While this makes SSNC appear like a stock to avoid or sell if you own it, you might change your mind after gaining a better understanding of the assumptions behind the P/E ratio. In this article, I will break down what the P/E ratio is, how to interpret it and what to watch out for. (17-0)
Investors interested in Financial Transaction Services stocks are likely familiar with VeriFone Systems (PAY - Free Report) and Envestnet (ENV - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. (5-0)
Good day, everyone, and welcome to the Envestnet First Quarter 2018 Earnings Conference Call. Today's call is being recorded. (2-0)
Tolstoy wrote, "happy families are all alike; every unhappy family is unhappy in its own way." Can a similar thing be said about bad stocks? I'm beginning to think so.
How much of SS&C's $5.4-billion buy of DST Systems trickles down to Black Diamond RIAs? Maybe a good bit (4-0)
as of ET